Document is current
Any future updates will be listed below
-
Authors
Lopez-Fabuel, Irene https://orcid.org/0000-0002-3049-748X
Garcia-Macia, Marina https://orcid.org/0000-0002-3908-9060
Buondelmonte, Costantina
Burmistrova, Olga
Bonora, Nicolo
Alonso-Batan, Paula
Morant-Ferrando, Brenda
Vicente-Gutierrez, Carlos https://orcid.org/0000-0002-6481-595X
Jimenez-Blasco, Daniel
Quintana-Cabrera, Ruben https://orcid.org/0000-0002-0601-349X
Fernandez, Emilio
Llop, Jordi
Ramos-Cabrer, Pedro https://orcid.org/0000-0003-0368-7031
Sharaireh, Aseel
Guevara-Ferrer, Marta https://orcid.org/0000-0002-5334-3344
Fitzpatrick, Lorna
Thompton, Christopher D.
McKay, Tristan R.
Storch, Stephan
Medina, Diego L. https://orcid.org/0000-0002-7347-2645
Mole, Sara E. https://orcid.org/0000-0003-4385-4957
Fedichev, Peter O.
Almeida, Angeles https://orcid.org/0000-0003-0485-8904
Bolaños, Juan P. https://orcid.org/0000-0002-3949-6862
- License Information
-
More Information
Article History
Received: 5 November 2020
Accepted: 12 January 2022
First Online: 27 January 2022
Competing interests
: P.O.F. is a shareholder and O.B. is an employee of Gero Discovery LLC, a company developing PFKFB3 inhibitors. The remaining authors declare no competing interests.
